Sage Journals: Discover world-class research

Abstract

Hypoactive Sexual Desire Disorder (HSDD) is defined as a persistent or recurrent deficiency of sexual fantasies and desire for sexual activity, which causes marked personal distress or interpersonal difficulty, and is not better accounted for by another psychiatric disorder or the direct physiological effects of a substance (e.g., a medication) or medical condition. HSDD is believed to be the most common form of Female Sexual Dysfunction and is associated with emotional distress and relationship problems. No pharmacologic therapy is approved for the treatment of HSDD in premenopausal or naturally postmenopausal women. Flibanserin is a 5-HT_1A agonist/5-HT_2A antagonist that is under investigation as a treatment for HSDD in women. The aim of this article is to present an overview of the pharmacology, clinical efficacy and safety of flibanserin. Flibanserin is an investigational drug that is not licensed for any indication in any country.

Keywords

Female Sexual Dysfunction flibanserin Hypoactive Sexual Desire Disorder

Hypoactive Sexual Desire Disorder (HSDD) is defined by the American Psychiatric Association in its Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty and that is not better accounted for by another psychiatric condition, medical condition or substance (e.g., a medication) [1]. As with other types of Female Sexual Dysfunction (FSD), HSDD is further classified as being either lifelong (present from the onset of sexual functioning) or acquired (developed after a period of normal functioning) and as either situational (limited to certain partners, situations or types of stimulation) or generalized [1].

Diagnosis of HSDD is made by a clinician taking into account the biologic, psychosocial, relationship and cultural factors that may be contributing to the woman's lack of sexual desire, and whether the woman is troubled by her lack of desire [1,2]. It is essential that healthcare professionals adopt a patient-centered approach to the evaluation of sexual disorders and take a thorough medical, sexual and psychosocial history [2]. A number of checklists, screeners and diagnostic instruments have been developed to aid clinicians in the evaluation of women presenting with sexual problems [2]. For those presenting with low sexual desire, these include the Decreased Sexual Desire Screener, a brief diagnostic instrument for generalized acquired HSDD designed for use by clinicians with little or no expertise in the diagnosis of female sexual disorders [3]. Such instruments are particularly important in primary care, where time for patient consultations is limited.

Epidemiologic studies have found that approximately one in ten women report having low sexual desire associated with distress, which may be HSDD [4,5]. Occurring in pre-, peri- and post-menopausal women, HSDD is associated with emotional distress, lower sexual satisfaction for both the patient and her partner, and impairments in general health status and quality of life [5 –10]. However, HSDD remains under-recognized, underdiagnosed and undertreated. The majority of physicians are reluctant to ask their female patients about their sexual health as they are poorly trained in female sexual health, have only a short time for consultations and lack effective treatment options [11 –14].

At present, there are no approved pharmaceutical treatments for HSDD outside Europe. In Europe, the only approved agent is a testosterone patch (Intrinsa®; Procter & Gamble Pharmaceuticals), which is licensed solely for use in surgically menopausal women with HSDD who are receiving estrogen therapy. The aim of this article is to present an overview of flibanserin (Boehringer Ingelheim), a potential new treatment for HSDD in premenopausal women that is in late-stage clinical development. At present, flibanserin is an investigational drug that is not licensed for any indication in any country.

Overview of the market

There are no official treatment guidelines for HSDD. However, a committee of experts in FSD, convened as part of the 3rd International Consultation on Sexual Medicine (ICSM), and have published recommendations on the management of women with desire and arousal disorders [15]. Suggested treatments for low sexual desire include psychologic therapy, such as cognitive behavioral therapy [15]. However, while there is some evidence of benefit of cognitive behavioral therapy in women with desire problems [16 –18], randomized controlled data supporting the efficacy of psychologic counseling in women with HSDD are lacking [15].

Testosterone has been used as a treatment for low sexual desire since the 1930s, but systematic investigation into its use in this setting has been relatively recent [15]. The benefits of testosterone therapy in women with low desire remain controversial. In December 2004, the US FDA refused to approve a testosterone patch for the treatment of HSDD in women owing to insufficient safety data on the long-term effects of testosterone treatment in women [101]. This safety concern was predominantly driven by the findings of the Women's Health Initiative, which found an increased risk of breast cancer and cardiovascular effects in women who took hormonal therapies combining progesterone with estrogen [19]. The same testosterone patch was approved in some European countries for the treatment of HSDD in surgically menopausal women who are undergoing estrogen therapy [102]; however, it is not widely used. Recent recommendations from the 3rd ICSM state that current data are not adequate to support the use of testosterone therapy in pre- and peri-menopausal women, and that additional safety data are required before the long-term use of testosterone therapy can be recommended [15,20]. Safety data on testosterone therapy continues to be collected and 4 years of safety data on the safety of the testosterone patch in surgically menopausal women have recently been presented [21].

The lack of licensed pharmacologic treatments for HSDD has led to significant off-label prescription of drugs that are not licensed for HSDD, particularly antidepressants and hormones. In addition, many women with desire problems use over-the-counter medications that have no proven efficacy [22].

Introduction to flibanserin

Chemistry & pharmacology

Flibanserin (BIMT 17 BS; 2H-benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3(tri-fluoromethyl) phenyl]-1-piperazinyl]ethyl]) is a nonhormonal, centrally acting molecule that acts as an agonist at postsynaptic 5-HT_1A receptors and as an antagonist at 5-HT_2A receptors [23,24]. In rats, flibanserin administration has been shown to lead to brain region-specific decreases in serotonin (5-HT) and increases in dopamine and norepinephrine [25]. Dopamine and norepinephrine are involved in the ‘excitement’ phase of the sexual response (e.g., desire and arousal) while 5-HT is involved in the ‘inhibitory’ phase (e.g., satiety or refractory period) [26]. A balance between excitatory activity driven by dopamine and norepinephrine and inhibitory activity driven by 5-HT is believed to be necessary for a healthy sexual response [26]. One hypothesis suggests that an imbalance between these systems may be present in sexual dysfunction. By selectively modulating these neurotransmitters in specific brain areas, flibanserin may act to re-balance these systems in women with HSDD.

Following chronic oral administration, flibanserin plasma concentrations rise rapidly, usually within the first hour, and decrease biexponentially thereafter (C_max,ss = 469 ng/ml; T_max = 45 to 60 min, AUCτ,ss = 2080 ng h/ml for 100 mg once-daily dose). A total of 90% of the dose is absorbed, primarily from the upper intestine, and 33% of flibanserin is available systemically due to first-pass metabolism. The basic pharmacokinetic properties of flibanserin demonstrate adequate exposure to flibanserin for once-daily administration due to its terminal half-life of approximately 10 h. Flibanserin exposure can be controlled as there is moderate accumulation (accumulation ratio for AUC 1.44 after once-daily 100 mg dosing), a steady state is established within 3 days and plasma levels do not change afterwards (as observed during 2 weeks of chronic dosing). Flibanserin exposure is proportional to dose [BI data on file].

As expected for a centrally acting drug, the plasma protein binding of flibanserin (98% to albumin) is high. Flibanserin is nearly completely metabolized with at least 35 metabolites formed in humans, most of which occur in low concentrations in plasma or urine. Two metabolites could be characterized that show plasma concentrations similar to flibanserin: flibanserin-6-sulfate and flibanserin-6,21-disulfate These two metabolites were thoroughly assessed in receptor assays and are not considered to be active [BI data on file].

Flibanserin metabolites are primarily excreted in urine (44.1%) and feces (50.9%). Hepatic impairment causes a pronounced increase in flibanserin exposure, but renal impairment does not. In regard to metabolic drug–drug interactions, flibanserin exposure can be affected by alterations in cytochrome P450 (CYP)3A4 activity, which is the major isoform involved in the metabolism of flibanserin, but not by impaired CYP2D6 function, which plays a minor role in flibanserin metabolism. No clinically relevant effect of flibanserin has been observed on the pharmacokinetics of simvastatin, a substrate of CYP3A4; bupropion, a substrate of CYP2B6; or a combination of levonorgestrel and ethinyl estradiol. Flibanserin can be given with or without food. Food increases flibanserin systemic exposure by up to 56%, but only has a minimal effect on the maximum plasma concentrations and typical flibanserin side effects [BI data on file].

Rationale for clinical development program

Acting as a cortical 5-HT_1A agonist and 5-HT_2A antagonist, flibanserin was initially expected to possess antidepressant characteristics [23]. Preclinical studies demonstrated that flibanserin displayed antidepressant-like activity in most animal models sensitive to antidepressant drugs; however, its activity appeared to be qualitatively different from that of known antidepressants [23].

When investigated as a potential treatment for Major Depressive Disorder (MDD) in Phase II/IIb trials, flibanserin was found not to be an effective antidepressant in active controlled studies [27]. However, in women whose depressive symptoms included decreased sexual desire at baseline, flibanserin was found to be superior to a placebo and the comparator antidepressant (paroxetine) on the Arizona Sexual Experiences Scale (ASEX) [28], particularly on the ‘sex drive’ item [27]. These findings provided a rationale for beginning a clinical development program in women with HSDD.

Clinical efficacy

Phase II proof-of-concept trials

Two proof-of-concept trials with identical design were conducted in premenopausal women with HSDD. Both were 12-week, randomized, double-blind, placebo-controlled trials. Flibanserin was initiated at 50 mg twice daily, with optional uptitration to 100 mg twice daily at the end of week 8. The trials included women aged 18–45 years with a diagnosis of HSDD (DSM-IV-TR) [1] of 24 weeks or longer. Study participants were also required to have an ASEX sex drive (desire) score [28] of 5 (very weak) or 6 (none), and to be in a stable, monogamous, heterosexual relationship with a sexually functional partner. Key exclusion criteria were sexual aversion disorder, sexual pain disorders, psychiatric disorders likely to affect sexual functioning (including MDD), a history of any serious clinical disorder and use of any medication known to induce sexual dysfunction during the past 6 months.

Since there were no established end points for trials in HSDD when these trials were planned, a number of exploratory efficacy measures were used, including the ASEX (chosen as the primary end point based on observations from the Phase II/IIb MDD trials) [27], the Female Sexual Function Index (FSFI) [29], a version of the Changes in Sexual Functioning Questionnaire-Female (CSFQ-F) [30] that was self-administered over the telephone using an automated system, the Female Sexual Behavior Questionnaire (FSBQ, a simple self-administered weekly questionnaire designed to gather counts of sexual encounters, Satisfying Sexual Events [SSE], number of days with sexual thoughts or sexual fantasies and number of days with desire to engage in sexual activity), the preliminary 17-item version of the Sexual Interest and Desire Inventory-Female (SIDI-F) [31], the sum of the 12 core items of the SIDI-F and the Clinical Global Impression of Improvement (CGI-I) [32].

In the two trials, 148 patients received placebo and 149 patients received flibanserin. The trials were completed by 106 (71.6%) patients on placebo and by 77 (51.7%) patients on flibanserin. Adverse events (AEs) led to discontinuation in 36.2% of patients treated with flibanserin, compared with 5.4% of placebo patients. Flibanserin AE dropouts were mainly due to sedative effects of the morning dose, which at the 50 mg twice daily level, and especially at the 100 mg twice daily level (used in the last 4 weeks of treatment by 51.7% of patients) tend to interfere with morning work for approximately 1 h [BI data on file].

In a post-hoc pooled analysis of the two trials using the Last Observation Carried Forward method with either the per protocol set (completers without major protocol deviations) or the full analysis set, flibanserin was superior to placebo on the measures of sexual desire (ASEX sex drive, FSFI desire domain, CSFQ-F desire subscales, SIDI-F core symptoms, FSBQ sexual thoughts or fantasies and FSBQ desire to engage in sexual activity) at either the preassigned statistical level (p < 0.05) or at a trend level (p < 0.1) (Table 1). Flibanserin was superior to placebo on SSE at weeks 4, 8 and 12 for the per protocol set (p < 0.01). In the full analysis set, flibanserin showed a trend towards superiority on SSE at week 12. Individual trial data supported the pooled analysis; For example, CGI-I demonstrated that flibanserin was superior to placebo in each study at weeks 4, 8 and 12 at either a significance level (p < 0.05) or a trend level (p < 0.1). Thus, across a broad variety of measures, the trials demonstrated a sufficiently consistent efficacy to raise interest in investigating flibanserin in Phase III trials for the treatment of HSDD in women (Table 1).

Table 1.

Summary of pooled analysis of Phase II proof-of-concept trials in premenopausal women with Hypoactive Sexual Desire Disorder.

End point	Full analysis set			Per protocol set
	Placebo	FLI	p-value	Placebo	FLI	p-value
SSE	1.20 (0.28)	1.77 (0.29)	0.15	1.10 (0.32)	2.75 (0.37)	0.0005
ASEX ‘sex drive’ (desire) item	0.67 (0.09)	0.96 (0.09)	0.02	0.70 (0.11)	1.26 (0.14)	0.001
FSBQ sexual thoughts or fantasies	1.63 (0.33)	2.81 (0.34)	0.01	1.72 (0.42)	3.38 (0.49)	0.007
FSBQ desire for sex	1.50 (0.31)	2.25 (0.32)	0.091	1.61 (0.38)	3.43 (0.44)	0.001
SIDI-F 12-item†	5.93 (0.90)	9.28 (0.90)	0.0073	5.70 (1.10)	11.74 (1.30)	0.0003
CSFQ Desire/Frequency	0.39 (0.11)	0.85 (0.11)	0.003	0.37 (0.13)	1.07 (0.15)	0.0003
CSFQ Desire/Interest	0.65 (0.16)	1.16 (0.17)	0.03	0.69 (0.20)	1.52 (0.24)	0.005
FSFI total	2.27 (0.57)	4.80 (0.58)	0.002	2.38 (0.68)	6.16 (0.81)	0.0002
FSFI desire domain	0.51 (0.09)	0.86 (0.09)	0.006	0.51 (0.11)	1.05 (0.13)	0.002
CGI-I ‘much or very much improved’	18 (13.3)	33 (24.8)	0.02	17 (17.5)	23 (33.8)	0.01

Values shown are least squares mean (standard error) change from baseline, except for CGI-I ‘much improved’, for which values are n (%), for the full analysis set and the per protocol set (both Last Observation Carried Forward).

†

12 core items of the 17-item inventory.

ASEX: Arizona Sexual Experiences Scale; CGI-I: Clinical Global Impression of Improvement; CSFQ: Changes in Sexual Functioning Questionnaire; FLI: Flibanserin

FSBQ: Female Sexual Behavior Questionnaire; FSFI: Female Sexual Function Index; SIDI-F: Sexual Interest and Desire Inventory-Female; SSE: Satisfying Sexual Event.

Phase III clinical development program: the BOUQUET studies

Overview of Phase III trials

The Phase III trials of flibanserin in women with HSDD are collectively known as the BOUQUET studies. Five Phase III trials in premenopausal women have been completed and results reported:

Three North American, 24-week, randomized, placebo-controlled trials: DAHLIA (511.70) [33], VIOLET (511.71) [34] and DAISY (511.75) [35]

One European (13 countries), 24-week, randomized, placebo-controlled trial: ORCHID (511.77) [36]

A randomized withdrawal trial (ROSE [511.74]) in which patients received 24-weeks' open-label treatment with flibanserin and then participants who met prespecified enrichment criteria were randomized in a double-blind manner to receive flibanserin or placebo for 24 weeks, to assess potential withdrawal effects [37 –40].

The BOUQUET program also includes two extension trials:

SUNFLOWER (511.84), an extension study in which patients who completed a North American trial received open-label treatment with flibanserin for 52 weeks

MAGNOLIA (511.118), an extension study in which patients who completed the ORCHID trial received open-label treatment with flibanserin for 28 weeks

Overall, the premenopausal program involves approximately 5000 patients.

Phase III randomized placebo-controlled trials

North American trials: DAHLIA, VIOLET, DAISY

The objectives of these trials were to establish the efficacy of flibanserin over 24 weeks of treatment to produce a clinically meaningful therapeutic response in premenopausal women with generalized acquired HSDD, and to document the safety profile of flibanserin administered to such women for 24 weeks. The three trials had an almost identical design (Figure 1) [41]. Each trial included a 4-week baseline period followed by a 24-week treatment period, during which patients received either flibanserin or placebo. The trials differed in the dosing regimens investigated for flibanserin: 25 mg twice daily, 50 mg twice daily and 50 mg once daily at bedtime in DAHLIA; 50 mg once daily at bedtime and 100 mg once daily at bedtime in VIOLET; and 25 mg twice daily, 50 mg twice daily (uptitrated from 50 mg once daily at bedtime at week 2) and 100 mg once daily at bedtime (uptitrated from 50 mg once daily at bedtime at week 2) in DAISY.

Figure 1.

Design of pivotal trials.

The trials included women aged 18 years or over with a diagnosis of generalized acquired HSDD (DSM-IV-TR) [1] of a duration of 24 weeks or more, who were premenopausal according to Stages of Reproductive Aging Workshop criteria [42]. The diagnosis of generalized acquired HSDD was made by a clinician following a structured diagnostic interview. Participants were required to have a score of 15 or above on the Female Sexual Distress Scale-Revised (FSDS-R) [43], indicating that they were distressed about their sexual dysfunction, and to score a rating of ‘0’ or ‘1’ on item two (receptivity) of the SIDI-F [44 –46], indicating little or no receptivity to approach by their partner (Table 2). Participants had to be in a stable, communicative, monogamous, heterosexual relationship of a duration of 1 year or more, with a sexually functional partner; and to be compliant with using the eDiary for HSDD trials, an electronic diary used to collect data on sexual events and sexual desire during the trials (Table 2), and during the 4-week baseline period. Key exclusion criteria were sexual aversion disorder or a sexual pain disorder, psychiatric disorders likely to affect sexual functioning (including MDD), a history of any serious clinical disorder, pregnancy (current or within the previous 6 months), and the use of any medication that, in the investigator's opinion, might enhance or diminish sexual functioning within 4 weeks prior to entering the trial. Women were not eligible to enter the trial if they had received psychotherapeutic treatment within the previous 12 weeks, or experienced a major life stress (e.g., loss of income or death of a family member) or relationship discord that could interfere with sexual activity (except distress about HSDD).

Table 2.

Description of measures used in Phase III flibanserin clinical trials.

Measure	Description	Ref.
eDiary for HSDD trials	A handheld electronic device used by study participants to record their most intense level of sexual desire, sexual events and whether sexual events were satisfying to them, on a daily basis
eDiary desire score	Monthly sum of responses to the daily eDiary desire question, ‘Indicate your most intense level of sexual desire in the last 24 hours’ (response options: 0 [no desire], 1 [low desire], 2 [moderate desire], or 3 [strong desire])
FSFI	19-item, self-report measure of sexual function, which assesses six domains of sexual function: desire, arousal, lubrication, orgasm, satisfaction and pain	[29]
FSFI desire domain	2-item domain within the FSFI that asks women about the frequency and level of their sexual desire
FSDS-R	Extended version of the FSDS (a 12-item self-administered questionnaire that measures sex-related personal distress in women). The FSDS-R includes one additional question (Item 13) that specifically assesses distress due to low sexual desire	[43]
FSDS-R Item 13	FSDS-R question that asks a woman how often she feels bothered by low sexual desire	[43]
PGI-I	Simple evaluation completed by the patient to assess the overall change in her condition (i.e., decreased sexual desire and feeling bothered by it) compared with when she started study medication; rated from 1 (very much improved) through 4 (no change) to 7 (very much worse)
PBE	Single question asked upon treatment discontinuation: ‘Overall, do you believe that you have experienced a meaningful benefit from the study medication?’ (Yes/No)
SSE	A sexual event was defined as sexual intercourse, oral sex, and partner-initiated or self-masturbation. An SSE was recorded when a patient said that a sexual event was satisfying for her
SIDI-F	13-item clinician-administered instrument to quantify the severity of symptoms in women with HSDD. Item 2 assesses receptivity to approach by partner for sex	[44]

FSDS-R: Female Sexual Distress Scale-Revised; FSFI: Female Sexual Function Index; HSDD: Hypoactive Sexual Desire Disorder; PBE: Patient Benefit Evaluation

PGI-I: Patient's Global Impression of Improvement; SIDI-F: Sexual Interest and Desire Inventory-Female; SSE: Satisfying Sexual Event.

The eDiary is a handheld electronic diary that prompted the participants on a daily basis to answer questions on their sexual activity, whether this activity was satisfying to them and their most intense level of sexual desire. A sexual event was defined for the participants as sexual intercourse, oral sex, masturbation or genital stimulation by their partner. An SSE was recorded when a woman reported that a recorded sexual event was satisfying for her. The desire question in the eDiary was ‘Indicate your most intense level of sexual desire in the last 24 h’, with responses scored on a four-point scale of 0 (no desire), 1 (low desire), 2 (moderate desire) or 3 (strong desire) (Table 2).

The coprimary end points were change from baseline in number of SSE/month and sexual desire score, both measured using the eDiary (Table 2). Secondary end points were FSDS-R total score and its Item 13 score, FSFI total score and FSFI desire domain score, Patient's Global Impression of Improvement (PGI-I), Patient Benefit Evaluation (PBE) and PGI-I-anchored responder end points (i.e., responders on SSE, eDiary desire score, FSDS-R Item 13, FSDS-R total score, FSFI desire domain score, FSFI total score) (Table 2). The selection of SSE as a coprimary end point was made in reference to the FDA's draft guidance on the development of drugs for FSD, which recommends that data on sexual events or encounters should be recorded daily by study subjects using diaries and that end points should include the number of successful and satisfactory sexual events or encounters over time (with the judgment of ‘successful’ and ‘satisfactory’ made by the patient) [103]. Currently there is no successful roadmap for FDA approval for a medication to treat HSDD, partly due to the difficulties in measuring a complex cognitive experience such as sexual desire [47].

European trial: ORCHID (511.77)

The objectives and design of ORCHID were essentially the same as for the North American trials (Figure 1). However, in ORCHID, the primary end point was change from baseline in number of SSE/month. Secondary end points included eDiary desire score, FSFI desire domain score, FSFI total score, FSDS-R Item 13 and total score, PGI-I and PBE, and the same responder end points as in the North American trials. The flibanserin dosing regimens investigated were 50 mg once daily at bedtime and 100 mg once daily at bedtime (uptitrated from 50 mg once daily at bedtime at week 2) [36].

Baseline characteristics

Across all four trials, there were no notable differences between the placebo and flibanserin treatment groups in baseline characteristics. The mean (SD) age of the North American participants was 35.4 (7.0) years and the mean (SD) age of the European population was 35.2 (7.2) years.

At baseline, the mean FSDS-R total score was 31.0 in all the North American trials and 28.2 in the European trial, approximately double the cutoff score of 15 for sexual distress [48]. The mean FSFI total score at baseline was 19.2 in all the North American trials and 18.8 in the European trial, well below the cutoff score of 26.55 for sexual dysfunction [49]. The mean FSFI desire domain score at baseline was 1.8 in all the North American trials and 1.9 in the European trial, in both cases below the cutoff score (≤3) established to distinguish women with HSDD from healthy controls [50]. At baseline, the mean SSE per month was 2.7 in all the North American trials and 2.3 in the European trial. Unlike criteria such as sexual distress or sexual dysfunction, SSE does not form part of the diagnostic criteria for HSDD. Consequently, no cutoff for a ‘dysfunctional’ level of SSE has been published so far. Indeed, a decrease in SSE in HSDD is considered to be an epiphenomenon or a ‘downstream’ consequence of a loss of sexual desire [51].

Patient disposition

Patient disposition differed according to the treatment group, and was primarily driven by dropouts due to AEs, which were dose- and regimen-related (Table 3).

Table 3.

Summary of patient disposition in the North American and European pivotal trials (DAISY, VIOLET, DAHLIA and ORCHID).

	Flibanserin				Placebo
	25 mg b.i.d.	50 mg q.h.s.	50 mg b.i.d.	100 mg q.h.s.

Treated (n)	733	969	728	1001	1360
Discontinued (%)	30.6	28.9	39.7	34.9	27.4
Adverse events	7.0	10.3	20.6	14.6	7.1
Noncompliance with protocol	3.0	3.6	2.7	3.5	3.0
Lost to follow-up	5.0	4.0	4.8	4.2	4.1
Consent withdrawn	11.1	5.7	7.0	6.3	7.6
Lack of efficacy	3.4	3.2	2.7	3.9	3.4
Other	2.1	2.1	1.8	2.4	2.1

Results from randomized placebo-controlled trials

Flibanserin 100 mg once daily at bedtime was found to be efficacious and well tolerated [52]. Other doses of flibanserin were found to have inconsistent efficacy [33 –36]. The Phase III statistical analysis plan included a prespecified pooled analysis of data on the flibanserin 100 mg once daily at bedtime dose from the two North American trials that investigated this dose (DAISY and VIOLET). The results of all doses tested in the individual trials have been presented elsewhere [33 –36] and differed little from the pooled results. This paper summarizes the efficacy results of the 100 mg once daily at bedtime dose from the North American trials (DAISY and VIOLET), the European trial (ORCHID), the prespecified pooled analysis of the DAISY and VIOLET trials, and the post hoc responder and remitter analysis of the pooled data from the DAISY, VIOLET and ORCHID trials. Safety and tolerability data from all Phase III trials and all doses will be presented.

Efficacy data for flibanserin 100 mg once daily at bedtime

North American trial, DAISY: primary & secondary end points

The mean change from baseline to week 24 (end of trial) in SSE/month was 1.9 for flibanserin verses 1.1 for placebo (p < 0.01; Table 4 ) [35]. For eDiary desire score, the mean change from baseline to week 24 was 8.5 for flibanserin verses 6.8 for placebo (p = 0.12; Table 4 ) [35]. Flibanserin was significantly superior to placebo on FSDS-R Item 13, FSDS-R total score, FSFI desire domain and FSFI total scores (p < 0.01, for all; Table 4 ) [35].

Table 4.

Summary of efficacy results for flibanserin 100 mg once daily at bedtime versus placebo.

End point	North American pivotal trial: VIOLET [34]			North American pivotal trial: DAISY [35]			North American pivotal trials: pooled data from DAISY and VIOLET			European pivotal trial: ORCHID [36]
	Placebo	Flibanserin 100 mg q.h.s.	p-value	Placebo	Flibanserin 100 mg q.h.s.	p-value	Placebo	Flibanserin 100 mg q.h.s.	p-value	Placebo	Flibanserin 100 mg q.h.s.	p-value
SSE†	0.8	1.6	<0.01	1.1	1.9	<0.01	1.0	1.7	<0.0001	0.9	1.5	0.14
eDiary desire score†	6.9	9.1	0.07	6.8	8.5	0.12	7.1	9.0	<0.05	5.4	7.7	<0.05
FSFI desire domain score	0.5	0.9	<0.0001	0.6	0.9	<0.0001	0.5	0.9	<0.0001	0.5	0.7	0.08
FSFI total score†	2.4	5.0	<0.0001	2.6	4.1	<0.01	2.5	4.4	<0.0001	2.5	3.4	0.14
FSDS-R Item 13 score†	−0.5	−0.8	<0.001	−0.5	−0.7	<0.001	−0.5	−0.8	<0.0001	−0.4	−0.6	<0.05
FSDS-R total score†	−4.9	−8.9	<0.0001	−5.2	−7.8	<0.001	−4.8	−8.0	<0.0001	−3.7	−6.4	<0.01

Data are presented for the North American pivotal trials (VIOLET, DAISY, and pooled analysis of VIOLET and DAISY) and European pivotal trial (ORCHID); full analysis set; Last Observation Carried Forward.

†

Mean change from baseline to end of trial.

FSDS-R: Female Sexual Distress Scale-Revised; FSFI: Female Sexual Function Index; SSE: Satisfying Sexual Event.

North American trial, VIOLET: primary & secondary end points

The mean change from baseline to week 24 (end of trial) in SSE/month was 1.6 for flibanserin verses 0.8 for placebo (p < 0.01; Table 4 ) [34]. The mean change from baseline to end of trial in eDiary desire score was 9.1 for flibanserin verses 6.9 for placebo (p = 0.07; Table 4 ) [34]. Flibanserin was significantly superior to placebo on FSDS-R Item 13, FSDS-R total score, FSFI desire domain and FSFI total scores (p < 0.001, for all; Table 4 ) [34].

North American trials, prespecified pooled analysis, VIOLET & DAISY: primary & secondary end points

The mean change from baseline to week 24 (end of trial) in SSE/month was 1.7 for flibanserin verses 1.0 for placebo (p < 0.0001; Table 4 ) [53]. For eDiary desire score, the change from baseline to week 24 was 9.0 for flibanserin verses 7.1 for placebo (p < 0.05; Table 4 ).

Flibanserin was significantly superior to placebo on FSFI desire domain score, FSDS-R Item 13, FSDS-R total score and FSFI total score (p < 0.01 for all) (Table 4) [53]. The number of patients reporting that their overall condition was ‘very much improved’, ‘much improved’ or ‘minimally improved’ on the PGI-I at week 24 was 48.3% for flibanserin verses 30.3% for placebo (p < 0.0001) [54]. Similarly, more women in the flibanserin group than women in the placebo group reported on the PBE that they had received a meaningful benefit from the study medication (p < 0.0001) [54].

European trial, ORCHID: primary & secondary end points

The mean change from baseline to week 24 (end of trial) in SSE/month was 1.5 for flibanserin verses 0.9 for placebo (p = 0.14; Table 4 ) [36]. For eDiary desire score, the change from baseline to week 24 was 7.7 for flibanserin verses 5.4 for placebo (p < 0.05; Table 4 ) [36]. Flibanserin was significantly superior to placebo on FSDS-R Item 13 and FSDS-R total score (p < 0.05 and p < 0.01, respectively), but not for FSFI desire domain or FSFI total scores (p = 0.08 and p = 0.14, respectively; Table 4 ) [36].

Post hoc PGI-I-anchored responder analyses (pooled data from North American [DAISY & VIOLET] & European [ORCHID] trials)

For every end point, the mean change from baseline was calculated and ‘anchored’ to every level of the PGI-I. The difference between ‘minimally improved’ and ‘no change’ on the PGI-I was used as the responder criterion, that is, women with values greater than the responder criterion were considered to be responders. Using this methodology, responders had improvements of greater than 1.39 in SSE, 7.87 in eDiary desire score, 0.81 in FSFI desire domain score (requiring a 2-point or greater increase in the sum of the two desire items, which provide a raw score before weighting of between 2 and 10), 4.57 in FSFI total score, −0.46 in FSDS-R Item 13 score (requiring a 1-point or greater decrease in the item's scoring from 0 to 4), or −5.31 (a six-point or greater decrease) in FSDS-R total score [55].

Compared with the placebo group, approximately a third more women receiving flibanserin 100 mg once daily at bedtime responded on SSE (32.6 vs 42.6%; p < 0.0001), FSFI desire domain score (30.6 vs 42.0%; p < 0.0001), and FSFI total score (31.4 vs 42.3%; p < 0.0001). Approximately a quarter more women on flibanserin 100 mg once daily at bedtime responded on FSDS-R Item 13 score (39.4 vs 49.4%; p < 0.0001) and FSDS-R total score (41.4 vs 53.2%; p < 0.0001) (Figure 2) [55].

Figure 2.

Results of Patient Global Impression of Improvement-anchored responder analyses conducted on pooled data for flibanserin 100 mg q.h.s. versus placebo from VIOLET, DAISY and ORCHID.

These results demonstrate that flibanserin 100 mg once daily at bedtime provides clinically as well as statistically meaningful benefits on sexual desire, overall sexual function, distress associated with sexual dysfunction, distress associated with low sexual desire and SSE.

Post hoc remitter analyses (pooled data from North American [DAISY & VIOLET] & European [ORCHID] trials)

Based on published cutoff points for differentiating women with and without sexual dysfunction, remitters were classified as patients who, at study end, had: FSDS-R total score less than 15 [48]; FSFI total score 26.55 or more [49]; or FSFI desire domain score (weighted score) of more than three [50].

This post hoc analysis showed that at study end, significantly higher proportions of patients were remitters following treatment with flibanserin 100 mg once daily at bedtime, compared with placebo, in terms of FSDS-R total score (27.9% for flibanserin 100 mg once daily at bedtime vs 19.7% for placebo; p < 0.0001), FSFI total score (38.0 vs 31.8%; p < 0.01), and FSFI desire domain score (31.3 vs 20.8%; p < 0.0001) [BI data on file].

ROSE (randomized withdrawal trial)

Design of ROSE study

The objectives of the ROSE trial were to determine if efficacy is maintained when premenopausal women with HSDD who have responded to 24 weeks of open-label treatment with flibanserin continue treatment for a further 24 weeks; to evaluate potential withdrawal effects from flibanserin over 24 weeks; and to assess the safety of flibanserin therapy over 48 weeks.

Inclusion and exclusion criteria for ROSE were the same as those used in the randomized placebo-controlled trials except that nonreceptivity (SIDI-F item two) was not required. The trial design is shown in Figure 3. Premenopausal women with generalized acquired HSDD were treated with open-label, flexible-dose flibanserin for 24 weeks. At week 24, women meeting predefined enrichment criteria were randomized to continued flibanserin therapy at optimized dosage or placebo. Stringent enrichment criteria were used: an increase of two SSE or more, or four or more desire days/month (a desire day was defined as a day for which a patient answered ‘low’, ‘moderate’ or ‘strong’ rather than ‘none’ to the eDiary question on desire). The coprimary end points were change from week 24 (randomization) baseline in SSE and eDiary desire score (Table 2). Secondary end points included FSFI desire domain score, FSFI total score, FSDS-R Item 13 score, FSDS-R total score and PGI-I (Table 2).

Figure 3.

Design of randomized withdrawal trial (ROSE).

Results of the ROSE study

Patient population

The demographics and baseline characteristics of patients participating in the ROSE trial were very similar to those in the randomized placebo-controlled trials [BI data on file].

Of the 738 patients entering the open-label phase of the study, 525 (71.1%) completed it. Of the patients who did not complete the open-label phase, 83 (11.2%) discontinued due to AEs. A total of 333 patients (45.1%) met the predefined enrichment criteria and were randomized to flibanserin (n = 163) or placebo (n = 170). Overall, 132 (81.0%) flibanserin and 146 (85.9%) placebo patients completed 48 weeks of treatment. During double-blind treatment, four (2.5%) patients treated with flibanserin discontinued due to AEs, compared with seven (4.1%) on placebo [40].

Primary & secondary efficacy end points

Over 24 weeks of open-label treatment, SSE and eDiary desire score increased by twofold and there was a threefold increase in the number of days in which desire was rated as moderate or strong [37]. From week 29 (i.e., 4 weeks postrandomization) to week 48, flibanserin was significantly superior to placebo on eDiary desire score (p < 0.05) [37]. At the end of the double-blind treatment period (weeks 45–48), flibanserin was significantly superior to placebo on SSE, FSFI desire domain score, FSFI total score, FSDS-R Item 13 score FSDS-R total score, and PGI-I (p < 0.05 for all) (Table 5) [37 –39].

Table 5.

Results of ROSE randomized withdrawal trial (double-blind period).

	Week 24 baseline		Change from week 24 baseline to week 48 (end of trial)
	Placebo	Flibanserin	Placebo	Flibanserin	p-value
Number treated	169†	163	170	163
SSE (standardized)	7. 2 (5.9)	6.9 (5.9)	−2.3	−1.4	0.0141
eDiary desire score	35.5 (16.6)	34.2 (16.2)	25.4	29.2	0.0283
FSFI desire items	3.6 (1.1)	3.6 (1.1)	0.8	0.5	0.0074
FSFI total score	28.6 (4.8)	28.8 (4.9)	4.0	1.9	0.0013
FSDS-R Item 13	1.9 (1.1)	1.8 (1.2)	−0.5	−0.2	0.0143
FSDS-R total score	17.0 (11.3)	15.2 (10.4)	−4.4	−1.5	0.0038
PGI-I	2.4 (0.9)	2.5 (1.0)	0.8	0.5	0.0106

†

170 for FSDS-R and FSDR-R Item 13.

FSDS-R: Female Sexual Distress Scale-Revised; FSFI: Female Sexual Function Index; PGI-I: Patient's Global Impression of Improvement; SSE: Satisfying Sexual Event.

Safety & tolerability

Exposure

Flibanserin has been tested in healthy volunteers (0.1–150 mg; n = 803 [432 women, 371 men]; mean age: 35.9 years; age range: 18–73 years), depressed patients (2–100 mg twice daily; n = 1210 [702 women, 508 men]; mean age of women patients: 41.4 years; age range of women patients: 18–45 years), and premenopausal women with HSDD (25–100 mg twice daily; n ≥ 4318). Over 6500 human subjects have received 1 dose or more of flibanserin in clinical trials to date. In the four randomized, placebo-controlled HSDD trials, 1729 women were exposed to flibanserin at a dosage of 100 mg/day (100 mg once daily at bedtime or 50 mg twice daily).

Proof of concept trial data

In the two proofs of concept trials, flibanserin was initiated at 50 mg twice daily, with optional uptitration to 100 mg twice daily at the end of week 8. Overall, 51.7% of patients in the flibanserin group uptitrated to 100 mg twice daily. The most frequently reported AEs in patients receiving flibanserin were somnolence (25.5 vs 2.0% for placebo), dizziness (25.5 vs 4.1%), nausea (24.8 vs 8.8%), sedation (18.8 vs 3.4%) and fatigue (18.1 vs 6.1%). There were no deaths or serious AEs, and other safety measures (i.e., blood pressure, pulse and laboratory tests) were unaffected by treatment [BI data on file].

Phase III data

Randomized controlled trials: DAHLIA, VIOLET, DAISY & ORCHID

Safety assessments included the evaluation of AEs, clinical laboratory parameters (i.e., hematology, chemistry, urinalysis and sex hormones), vital signs, physical findings and electrocardiogram data. There were no important differences in the frequencies of AEs reported in the North American and European trials. Across the four trials, AEs were reported by 66.2% of patients who received flibanserin and 57.7% of patients who received placebo [56]. The majority of AEs were of mild intensity, emerged during the first 14 days of treatment and resolved during the trial.

AEs were dose related (Table 6). Of the patients receiving flibanserin 100 mg once daily at bedtime, 69.5% reported one or more AE(s), compared with 57.7% of patients who received placebo. AEs occurring in 2% or more of patients in any flibanserin group and at twice the rate of placebo were dizziness (12.0%), nausea (11.9%), fatigue (11.0%), somnolence (9.5%), insomnia (5.1%), dry mouth (2.3%) and anxiety (2.0%) (Table 6) [56]. The less frequent side effects were sedation and constipation at approximately 2% each, and sleep disorder, rash, palpitations and pruritus at approximately 1% each, plus hypotension at approximately 0.4%.

Table 6.

Summary of adverse events reported during flibanserin pivotal trials (DAHLIA, DAISY, VIOLET and ORCHID).

	Placebo	Flibanserin
	n = 1360	25 mg b.i.d. n = 733	50 mg q.h.s. n = 969	50 mg b.i.d. n = 728	100 mg q.h.s. n = 1001
Patients reporting ≥1 AE, %	57.7	58.7	64.8	71.0	69.5
Patients reporting ≥1 serious AE, %	0.6	0.5	0.6	0.4	0.9
AEs occurring in ≥2% of patients in any flibanserin group and at twice the rate of placebo, %
– Dizziness	2.5	4.2	6.3	15.3	12.0
– Nausea	4.3	5.6	7.0	12.4	11.9
– Fatigue	5.7	4.8	6.1	13.9	11.0
– Somnolence	2.9	7.0	5.7	16.8	9.5
– Insomnia	2.4	1.9	2.0	2.8	5.1
– Dry mouth	0.7	0.8	1.2	1.4	2.3
– Anxiety	0.7	0.7	2.0	1.4	2.0
Patients with AEs leading to discontinuation, %	6.8	6.8	10.2	20.3	14.6
AEs leading to discontinuation in ≥1% of patients in any flibanserin group, %
– Dizziness	0.1	0.3	0.9	4.0	1.8
– Nausea	0.2	0.3	0.5	2.5	1.6
– Anxiety	0.3	0.4	1.0	0.5	1.3
– Insomnia	0.2	0.1	0.3	0.8	1.3
– Fatigue	0.5	1.0	0.7	5.1	1.1
– Somnolence	0.5	0.4	0.4	4.0	0.8
– Headache	0.7	0.8	1.1	1.8	0.6

AE: Adverse event.

Data taken from [56].

Adverse events led to discontinuation of treatment in 14.6% of patients who received flibanserin 100 mg once daily at bedtime verses 6.8% of patients who received placebo (Table 6). For flibanserin 100 mg once daily at bedtime, the AEs most frequently leading to discontinuation (≥1% of patients) were dizziness (1.8%), nausea (1.6%), anxiety (1.3%), insomnia (1.3%) and fatigue (1.1%) (Table 6) [56].

No deaths occurred in any of the trials except for a woman who died as a passenger in an airplane crash. The incidence of serious AEs was less than 1% in all of the trials and no serious AEs were considered related to flibanserin. No more clinically significant changes in blood pressure, pulse rate, physical examinations, electrocardiogram or laboratory parameters were observed than with placebo, nor did results reflect trends or clinical concerns. The rates of significant weight change (defined as a change of ≥7%) in patients associated with flibanserin treatment were 5.1% for weight loss and 0.8% for weight gain.

The following AEs were of special interest in flibanserin's development program due to findings in earlier studies or at the request of a regulatory authority: depression, suicide/self-injury, hemorrhage and ophthalmologic examination. Suicidality and depression (as it may relate to suicidality) are a potential concern for all centrally acting agents, including flibanserin. As other serotonergic agents (peripherally acting 5-HT_2A inhibitors) have been tested as antiplatelet agents, the potential occurrence of hemorrhage was also of interest. Safety assessments showed that flibanserin was not associated with an increased risk of suicidality, depressive AEs, bleeding AEs or eye abnormalities, compared with placebo.

No excess compared with placebo was found with the use of flibanserin 100 mg once daily at bedtime in women with HSDD in overuse or withdrawal AE (abuse potential), hypersexuality, changes in sex hormones including indices of fecundity or adverse pregnancy outcomes (observations were limited to women whose treatment was stopped promptly upon discovery of pregnancy). Currently, results from adequate and well-controlled studies of flibanserin in pregnant women are unavailable.

Randomized withdrawal trial: ROSE

During the initial open-label phase of the ROSE trial, during which all patients received flibanserin, 511 out of 738 (69.2%) patients reported one or more AEs [40]. During the double-blind phase, the most frequently reported AEs (≥2% more patients in one group than the other) were diarrhea (3.7% for flibanserin vs 0.6% for placebo), dizziness (0.6% for flibanserin vs 2.9% for placebo), hypertension (0% for flibanserin vs 2.4% for placebo), nausea (2.5% for flibanserin vs 4.7% for placebo), sinusitis (4.9% for flibanserin vs 7.1% for placebo) and urinary tract infection (6.1% for flibanserin vs 3.5% for placebo). AEs leading to discontinuation occurred in 2.5 and 4.1% of patients in the flibanserin and placebo groups, respectively. No withdrawal reactions were reported upon switching from flibanserin to placebo after the first 24 weeks of exposure to flibanserin or following abrupt treatment discontinuation at week 48 [40].

Regulatory affairs

Flibanserin has not received marketing authorization or been approved for commercial use in any indication in any country.

Conclusion

Flibanserin 100 mg once daily at bedtime, the highest dose tested extensively in Phase III studies, has been shown to be superior to placebo for treating premenopausal women with generalized acquired HSDD. The consistent therapeutic effect in two well-controlled trials of the 100 mg once daily at bedtime dose regimen, and its use by most patients in a 1-year randomized withdrawal (efficacy maintenance) trial, support the claim to treat premenopausal women with flibanserin. Flibanserin 100 mg once daily at bedtime has been shown to be safe and well-tolerated, with no evidence of a withdrawal effect. Thus, the overall risk/benefit of flibanserin can be considered positive.

In the pooled North American trials, the flibanserin 100 mg once daily at bedtime group consistently showed a statistically significant difference from placebo for all of the important end points (SSE, FSFI desire domain score, FSFI total score, FSDS-R total score, FSDS-R Item 13). The European trial results were supportive. Responder end points anchored to PGI-I showed that flibanserin provided clinically meaningful as well as statistically significant improvements.

Side effects reported most frequently, and in higher proportions of subjects taking 100 mg flibanserin once daily at bedtime compared with placebo, were dizziness, nausea, fatigue and somnolence, at approximately 10–12% each, and insomnia, at approximately 5%.

Future perspective

Over the next 5–10 years, the field of FSD is expected to evolve rapidly in areas such as diagnosis, clinical measures, pathophysiology, pharmacologic understanding and therapeutics. The 5th revision of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders is expected in 2013 and some changes to the classification of female sexual disorders are expected. Since DSM-IV was published, large databases on women with sexual dysfunction have been collected, providing an opportunity to base diagnostic criteria on solid empirical evidence for the first time. Over the past year, the neurobiology of the sexual response has been elucidated in some biochemical and anatomic detail, and brain imaging studies are beginning to allow close correlation between animal and human pharmacology; in the future greater strides should be made. The 3rd International Consultation on Sexual Medicine conducted in 2009 proposed large changes to standards for clinical trials in FSD, which will lead to more rigorously conducted trials in the next several years. Over the next few years, we should see the first pharmacologic treatments licensed for the treatment of FSD in premenopausal and postmenopausal women. Combination therapy (medications plus sex/psychotherapy) may also become available and prove beneficial. All of the above, plus growing cooperation between medical and psychosocial researchers in sexual health, should mediate rapid advances in therapeutics in this field.

Over the next few years, our understanding of the therapeutic value of flibanserin should broaden considerably too. Clinical trials are in progress to evaluate flibanserin in postmenopausal women with HSDD, and in women with sexual dysfunction who are taking SSRI or SNRI antidepressants.

Information resources

The 3rd International Consultation on Sexual Medicine (ICSM) was conducted under the auspices of the International Consultation on Urological Diseases and the International Society for Sexual Medicine (ISSM). As part of this consultation, committees of experts in diverse areas of sexual medicine reviewed the scientific literature and developed their conclusions and recommendations. Summaries of the committees' findings were presented and discussed at the 3rd ICSM congress held in Paris in July 2009. Most of the committees' reports were published in the Journal of Sexual Medicine in January 2010 [57] and provide a valuable overview of the current literature. Several of the committees' reports are cited in this article.

Executive summary

Mechanism of action

Flibanserin is a novel 5-HT_1A agonist/5-HT_2A antagonist.

Flibanserin administration leads to brain region-specific increases in dopamine and norepinephrine (which are involved in the ‘excitement’ phase of the sexual response) and decreases in serotonin (5-HT) (which is involved in the ‘inhibitory’ phase).

It is hypothesized that by selectively modulating these neurotransmitters, flibanserin may act to rebalance systems that have become imbalanced in women with Hypoactive Sexual Desire Disorder (HSDD).

Pharmacokinetic properties

The absolute bioavailability of flibanserin after oral administration is 33.2%, and it is moderately distributed in body tissues, with a half-life of about 10 h.

Steady state is established within 3 days.

Flibanserin is nearly completely metabolized (mainly by CYP3A4); metabolites are primarily excreted via urine (44%) and feces (51 %).

Clinical efficacy

In North American premenopausal women with generalized acquired HSDD, 24 weeks' treatment with flibanserin 100 mg once daily at bedtime is associated with significant improvements versus placebo on all relevant end points, that are:

– Number of satisfying sexual events

– Sexual desire

– Distress associated with sexual dysfunction

– Overall sexual function

– Patient's Global Impression of Improvement

– Patient benefit evaluation

Responder end points anchored to the Patient's Global Impression of Improvement show that flibanserin produces improvements that are clinically meaningful to patients. Furthermore, a significant percentage of patients remit (no longer meet scale cutoffs for HSDD).

Safety & tolerability

Flibanserin is well-tolerated at doses up to 100 mg/day (the highest dose tested in Phase III) for 24 weeks.

The most frequent adverse events reported in patients taking flibanserin 100 mg once daily at bedtime are dizziness, nausea, fatigue, somnolence and insomnia.

Drug interactions

The metabolism of flibanserin is significantly inhibited by strong CYP3A4 inhibitors and greatly increased by CYP3A4 inducers.

No clinically relevant effect of flibanserin is observed on the pharmacokinetics of simvastatin, bupropion or a combination of levonorgestrel and ethinyl estradiol.

Dosage & administration

Flibanserin is administered orally.

The minimal effective dose of flibanserin is 100 mg once daily at bedtime.

Footnotes

The flibanserin trials/studies reported in the manuscript were funded by Boehringer Ingelheim. A Clayton has received grants from BioSante Pharmaceuticals, Inc., Boehringer-Ingelheim, Brain Resource Limited, BristolMyersSquibb, Pfizer, Inc., and Repligen Corporation. A Clayton has received advisory board fees/consultant fees from Boehringer-Ingelheim, BristolMyersSquibb, Eli Lilly and Company, Labopharm, Inc., New England Research Institutes, Pfizer, Inc., PGxHealth, Sanofi-aventis, Takeda, and TransTech Pharma, Inc., and she has received speaker's bureau/honorarium from Eli Lilly and Company. A Clayton has also received royalties/copyright from Ballantine Books/Random House, Guilford Publications and Healthcare Technology Systems, Inc. L Dennerstein has received research funding or consultancies, funding to attend conferences, speaker payments and is on expert panels for Boehringer-Ingelheim and Bayer Schering. R Pyke and M Sand are full-time employees of Boehringer Ingelheim. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Editorial assistance for this article was provided by J Scopes, Medical Writer, and W Morris, Director, both contracted by Fleishman-Hillard, an agency contracted by Boehringer Ingelheim.

References

Papers of special note have been highlighted as:.

of interest

of considerable interest.

American Psychiatric Association: DSM-IV: Diagnostic and Statistical Manual of Mental Disorders (4th Edition). Text revision. American Psychiatric Press, Washington, DC, USA (2000).

Provides a common language and standard criteria for the diagnosis of mental disorders.

Hatzichristou

Rosen

DeRogatis

: Recommendations for the clinical evaluation of men and women with sexual dysfunction. J. Sex. Med. 7(1–2), 337–348 (2010).

Clayton

Goldfischer

Goldstein

DeRogatis

Lewis-DAgostino

Pyke

: Validation of the Decreased Sexual Desire Screener (DSDS): a brief diagnostic instrument for generalized acquired female Hypoactive Sexual Desire Disorder (HSDD). J. Sex. Med. 6(3), 730–738 (2009).

Describes the validation of the Decreased Sexual Desire Screener as a sensitive and specific brief diagnostic instrument for the diagnosis of generalized acquired female Hypoactive Sexual Desire Disorder by clinicians who are neither trained nor specialized in Female Sexual Dysfunction.

Shifren

Monz

Russo

Segreti

Johannes

: Sexual problems and distress in United States women: prevalence and correlates. Obstet. Gynecol. 112(5), 970–978 (2008).

10.

Outlines the results of an epidemiologic study conducted in over 31,500 adult US women on the prevalence of sexual problems and sexual problems accompanied by personal distress, and their correlates.

11.

Dennerstein

Koochaki

Barton

Graziottin

: Hypoactive Sexual Desire Disorder in menopausal women: a survey of western European women. J. Sex. Med. 3(2), 212–222 (2006).

12.

Dennerstein

Hayes

Sand

Lehert

: Attitudes toward and frequency of partner interactions among women reporting decreased sexual desire. J. Sex. Med. 6(6), 1668–1673 (2009).

13.

Graziottin

Koochaki

Rodenberg

Dennerstein

: The prevalence of Hypoactive Sexual Desire Disorder in surgically menopausal women: an epidemiological study of women in four European countries. J. Sex. Med. 6(8), 2143–2153 (2009).

14.

Rosen

Shifren

Monz

Odom

Russo

Johannes

: Correlates of sexually related personal distress in women with low sexual desire. J. Sex. Med. 6(6), 1549–1560 (2009).

15.

Biddle

West

D'Aloisio

Wheeler

Borisov

Thorp

: Hypoactive Sexual Desire Disorder in postmenopausal women: quality of life and health burden. Value Health 12, 763–772 (2009).

16.

Revicki

Fisher

Rosen

Kuppermann

Margolis

Hanes

: The impact of Hypoactive Sexual Desire Disorder (HSDD) on women and their relationships: qualitative data from patient focus groups. J. Sex. Med. 7(Suppl. 3), 124–125 (2010).

17.

Kingsberg

: Identifying HSDD in the family medicine setting. J. Fam. Pract. 58(Suppl. 7), S22–S25 (2009).

18.

Harsh

McGarvey

Clayton

: Physician attitudes regarding Hypoactive Sexual Desire Disorder in a primary care clinic: a pilot study. J. Sex. Med. 5(3), 640–645 (2008).

19.

Parish

Clayton

: Sexual medicine education: review and commentary. J. Sex. Med. 4(2), 259–267 (2007).

20.

Abdolrasulnia

Shewchuk

Roepke

: Management of female sexual problems: perceived barriers, practice patterns, and confidence among primary care physicians and gynecologists. J. Sex. Med. 7(7), 2499–2508 (2010).

21.

Brotto

Bitzer

Laan

Leiblum

Luria

: Women's sexual desire and arousal disorders. J. Sex. Med. 7(1 Pt 2), 586–614 (2010).

22.

McCabe

: Evaluation of a cognitive behavior therapy program for people with sexual dysfunction. J. Sex. Marital Ther. 27(3), 259–271 (2001).

23.

Trudel

Marchland

Ravart

Aubin

Turgeon

Fortier

: The effect of a cognitive-behavioral group treatment program on hypoactive sexual desire in women. Sex. Rel. Ther. 16(2), 145–164 (2001).

24.

McCabe

Althof

Assalian

: Psychological and interpersonal dimensions of sexual function and dysfunction. J. Sex. Med. 7(1–2), 327–336 (2010).

25.

Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288(3), 321–333 (2002).

26.

Wierman

Nappi

Avis

: Endocrine aspects of women's sexual function. J. Sex. Med. 7(1–2), 561–585 (2010).

27.

Nachtigall

Casson

Lucas

Schofield

Melson

Simon

: The safety and tolerability of the transdermal testosterone patch for up to 4 years in surgically menopausal women on estrogen/progestin therapy. J. Sex. Med. 7(Suppl. 3), 142 (2010).

28.

Shifren

Johannes

Monz

Russo

Bennett

Rosen

: Help-seeking behavior of women with self-reported distressing sexual problems. J. Womens Health (Larchmt.) 18(4), 461–468 (2009).

29.

Borsini

Evans

Jason

Rohde

Alexander

Pollentier

: Pharmacology of flibanserin. CNS Drug Rev. 8(2), 117–142 (2002).

30.

Marazziti

Palego

Giromella

: Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain. Int. J. Neuropsychopharmacol. 5(2), 131–140 (2002).

31.

Allers

Dremencov

Ceci

: Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study. J Sex. Med. 7, 1757–1767 (2010).

32.

Describes the results of an animal study investigating the effects of flibanserin on neurotransmitters in brain areas associated with sexual behavior.

33.

Pfaus

: Pathways of sexual desire. J. Sex. Med. 6(6), 1506–1533 (2009).

34.

Presents a comprehensive review of evidence (human and animal) relating to neurochemical and neuroanatomical systems involved in sexual excitation and inhibition, and their role during normal and hypoactive sexual states.

35.

Kennedy

: Flibanserin: initial evidence of efficacy on sexual dysfunction in patients with Major Depressive Disorder. J. Sex. Med. (2010) (Epub ahead of print).

36.

McGahuey

Gelenberg

Laukes

: The Arizona Sexual Experiences Scale (ASEX): reliability and validity. J. Sex. Marital Ther. 26(1), 25–40 (2000).

37.

Rosen

Brown

Heiman

: The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J. Sex. Marital Ther. 26(2), 191–208 (2000).

38.

Describes the development and validation of the Female Sexual Function Index, a brief self-report measure of female sexual function.

39.

Clayton

McGarvey

Clavet

: The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol. Bull. 33(4), 731–745 (1997).

40.

Sills

Wunderlich

Pyke

: The Sexual Interest and Desire Inventory-Female (SIDI-F): item response analyses of data from women diagnosed with Hypoactive Sexual Desire Disorder. J. Sex. Med. 2(6), 801–818 (2005).

41.

US Department of Health, Education and Welfare: Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology (Revised Edition). Guy

(Ed.). MD, USA 216–222 (1976).

42.

Clayton

Jayne

Jacobs

Kimura

Pyke

Lewis-D'Agostino

: Efficacy of flibanserin as a potential treatment for Hypoactive Sexual Desire Disorder in North American premenopausal women: results from the DAHLIA trial. J. Sex. Med. 6(Suppl. 5), 408–420 (2009).

43.

Jolly

DeRogatis

Komer

: Efficacy of flibanserin as a potential treatment for Hypoactive Sexual Desire Disorder in North American premenopausal women: results from the VIOLET trial. J. Sex. Med. 6(Suppl. 5), 466 (2009).

44.

Thorp

Simon

Dattani

: Efficacy of flibanserin as a potential treatment for Hypoactive Sexual Desire Disorder in North American premenopausal women: results from the DAISY trial. J. Sex. Med. 6(Suppl. 5), 425 (2009).

45.

Nappi

Dean

van Lunsen

Hebert

Kimura

Pyke

: Efficacy of flibanserin as a potential treatment for Hypoactive Sexual Desire Disorder in European premenopausal women: results from the ORCHID trial. J. Sex. Med. 6(Suppl. 5), 409 (2009).

46.

Goldfischer

Cotton

Mikl

Pyke

Sand

: Efficacy of continued flibanserin treatment on sexual desire and satisfying sexual events in premenopausal women with HSDD: results from the ROSE study. J. Sex. Med. 5(Suppl. 3), 159 (2008).

47.

Goldfischer

Cotton

Mikl

Pyke

Sand

: Efficacy of continued flibanserin treatment on distress associated with sexual dysfunction in premenopausal women with HSDD: results from the ROSE study. J. Sex. Med. 5(Suppl. 3), 174 (2008).

48.

Goldfischer

Cotton

Mikl

Pyke

Sand

: Efficacy of continued flibanserin treatment on sexual functioning in premenopausal women with HSDD: results from the ROSE study. J. Sex. Med. 5(Suppl. 3), 159 (2008).

49.

Pyke

Goldfischer

Mikl

: Safety and tolerability of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from the ROSE study. Presented at: American Psychiatric Association 2008 Annual Meeting. Washington, DC, USA (2008).

50.

Jolly

Clayton

Thorp

Nappi

Kimura

Pyke

: Design of randomized controlled trials of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder. J. Sex. Med. 6(Suppl. 5), 465 (2009).

51.

Soules

Sherman

Parrott

: Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric 4(4), 267–272 (2001).

52.

DeRogatis

Clayton

D'Agostino

Lewis D

Wunderlich

: Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with Hypoactive Sexual Desire Disorder. J. Sex. Med. 5(2), 357–364 (2008).

53.

Clayton

Segraves

Leiblum

: Reliability and validity of the Sexual Interest and Desire Inventory-Female (SIDI-F), a scale designed to measure severity of female Hypoactive Sexual Desire Disorder. J. Sex. Marital Ther. 32(2), 115–135 (2006).

54.

Lewis-D'Agostino

Clayton

Wunderlich

Kimura

DeRogatis

Goldstein

: Validating the Sexual Interest and Desire Inventory-Female (SIDI-F) in North American women. Obstet. Gynecol. 109(Suppl. 4), S23 (2008).

55.

Nappi

van Lunsen

Tignol

Goldmeier

Pyke

Staehle

: Validation of the Sexual Interest and Desire Inventory-Female© (SIDI-F©) in European Women. J. Sex. Med. 5(Suppl. 2), 53 (2008).

56.

Althof

Rosen

DeRogatis

Corty

Quirk

Symonds

: Outcome measurement in Female Sexual Dysfunction clinical trials: review and recommendations. J. Sex. Marital. Ther. 31, 153–166 (2005).

57.

DeRogatis

Rosen

Leiblum

Burnett

Heiman

: The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J. Sex. Marital Ther. 28(4), 317–330 (2002).

58.

Wiegel

Meston

Rosen

: The Female Sexual Function Index (FSFI): cross-validation and development of clinical cutoff scores. J. Sex. Marital Ther. 31(1), 1–20 (2005).

59.

Gerstenberger

Rosen

Brewer

: Sexual desire and the Female Sexual Function Index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without Hypoactive Sexual Desire Disorder. J. Sex. Med. (2010) (Epub ahead of print).

60.

Clayton

Dennerstein

Fisher

Kingsberg

Perelman

Pyke

: Standards for clinical trials in sexual dysfunction in women: research designs and outcomes assessment. J. Sex. Med. 7(1–2), 541–560 (2010).

61.

Jolly

Clayton

Thorp

: Efficacy of flibanserin 100 mg qhs as a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women. J. Sex. Med. 6(Suppl. 5), 465 (2009).

62.

Jolly

Clayton

Thorp

Kimura

Sand

Pyke

: Efficacy of flibanserin 100 mg qhs as a potential treatment for Hypoactive Sexual Desire Disorder in North American premenopausal women. J. Sex. Med. 6(Suppl. 5), 465 (2009).

63.

Jolly

Thorp

Clayton

Kimura

Pyke

: Patient's perspective of efficacy of flibanserin in premenopausal women with HSDD. J. Sex. Med. 7, 133–134 (2010).

64.

Clayton

Jolly

Thorp

: Efficacy of flibanserin 100 mg qhs in premenopausal women with Hypoactive Sexual Desire Disorder: responder analyses. J. Sex. Med. 7(Suppl. 3), 122 (2010).

65.

Describes the results of a responder analysis in which changes in outcome measures were anchored to a patient-rated global measure of perceived improvement, which demonstrated that treatment with flibanserin results in benefits that are clinically meaningful to premenopausal women with Hypoactive Sexual Desire Disorder.

66.

Jolly

Clayton

Thorp

: Safety and tolerability of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder. J. Sex. Med. 6(Suppl. 5), 409 (2009).

67.

The 3rd International Consultation on Sexual Medicine (ICSM): International Consultation on Urological Diseases and the International Society for Sexual Medicine (ISSM). J. Sex Med. 7, 1–2 (2010).

68.

US FDA: Intrinsa advisory committee background document overview www.fda.gov/ohrms/dockets/ac/04/briefing/2004–4082B1_02_A-FDA-Intrinsa-Overview.doc.

69.

Intrinsa summary of product characteristics. Proctor & Gamble Pharmaceuticals. www.medicines.org.uk/EMC/medicine/19592/SPC/Intrinsa%20300%20micrograms%2024%20hours%20transdermal%20patch/.

70.

US DA: Draft guidance for industry. Female Sexual Dysfunction: clinical development of drug products for treatment www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071655.pdf.

Flibanserin: A Potential Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Women

Abstract

Keywords

Overview of the market

Introduction to flibanserin

Chemistry & pharmacology

Rationale for clinical development program

Clinical efficacy

Phase II proof-of-concept trials

Phase III clinical development program: the BOUQUET studies

Overview of Phase III trials

Phase III randomized placebo-controlled trials

North American trials: DAHLIA, VIOLET, DAISY

European trial: ORCHID (511.77)

Baseline characteristics

Patient disposition

Results from randomized placebo-controlled trials

Efficacy data for flibanserin 100 mg once daily at bedtime

North American trial, DAISY: primary & secondary end points

North American trial, VIOLET: primary & secondary end points

North American trials, prespecified pooled analysis, VIOLET & DAISY: primary & secondary end points

European trial, ORCHID: primary & secondary end points

Post hoc PGI-I-anchored responder analyses (pooled data from North American [DAISY & VIOLET] & European [ORCHID] trials)

Post hoc remitter analyses (pooled data from North American [DAISY & VIOLET] & European [ORCHID] trials)

ROSE (randomized withdrawal trial)

Design of ROSE study

Results of the ROSE study

Patient population

Primary & secondary efficacy end points

Safety & tolerability

Exposure

Proof of concept trial data

Phase III data

Randomized controlled trials: DAHLIA, VIOLET, DAISY & ORCHID

Randomized withdrawal trial: ROSE

Regulatory affairs

Conclusion

Future perspective

Information resources

Footnotes

References